Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Through 2029?

The market size for the pharmaceutical contract development and manufacturing organization (CDMO) for formulations has experienced significant expansion in the last few years. The value of the market is expected to increase from $49.32 billion in 2024 to $54.73 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 11.0%. The notable growth during the historical period is a result of the increase in pharmaceutical outsourcing, greater complexity in drug formulations, cost-reduction strategies by pharmaceutical corporations, a surge in demand for generics and biosimilars, as well as growth in small and mid-scale pharmaceutical companies.

Expect a swift expansion in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market in the next couple of years, as it’s projected to reach a staggering $82.15 billion in 2029 with a 10.7% compound annual growth rate (CAGR). This anticipated growth during the forecast period is due to several contributing factors. These include the rise in biologics and advanced therapies, broader input in personalized medicine, increased emphasis on continuous production, strong regulatory backing for outsourcing, and an upsurge in digitalization and manufacturing automation. Foreseen trends during this period encompass enhanced growth in continuous manufacturing, inclusion of AI and machine learning in drug advancement, improved handling capacity of high-potency API (HPAPI), an escalating trend of using biologics and intricate injectable formulations, and an emerging focus on ecologically friendly and sustainable manufacturing protocols.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25876&type=smp

What Market Forces Are Driving The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Sector In 2025 And Beyond?

The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market is anticipated to grow, prompted by substantial drug development and manufacturing activities. These terms encompass the expanding commitments of pharmaceutical and biopharmaceutical companies towards research, the creation of new drugs and production. The surge in such activities is largely owing to an increasing global demand for innovative and productive therapeutics. This pressure fuels the expansion of development pipelines and accelerates manufacturing schedules. By assisting in drug development, pharmaceutical CDMOs contribute to dosage formation and optimization, conduct stability tests and ensure regulatory compliance. They also oversee production and scale-up which leads to swift and economically efficient product launches. For example, data from the European Federation of Pharmaceutical Industries and Associations (EFPIA) for June 2023, stated that total pharmaceutical production in Europe came to $422,803 million (€390,000 million) in 2023, which was a rise from $393,857 million (€363,300 million) in 2022. As a result, flourishing drug development and manufacturing activities are triggering the development of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market.

How Is The Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Categorized By Segments?

The pharmaceutical contract development and manufacturing organization (cdmo) for formulations market covered in this report is segmented –

1) By Dosage Form: Oral Solids, Oral Liquids, Injectables, Topicals, Inhalation Products, Transdermal And Patches, Other Dosage Forms

2) By Therapeutic Area: Oncology, Cardiology, Central Nervous System, Gastroenterology, Infectious Diseases, Endocrinology

3) By End-User: Pharmaceutical Companies, Biopharmaceutical Companies, Other End-Users

Subsegments:

1) By Oral Solids: Tablets, Capsules, Granules, Powders, Modified-Release Formulations

2) By Oral Liquids: Syrups, Suspensions, Solutions, Emulsions, Elixirs

3) By Injectables: Vials, Ampoules, Prefilled Syringes, Lyophilized Injections, Injectable Emulsions

4) By Topicals: Creams, Ointments, Gels, Lotions, Foams,

5) By Inhalation Products: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizer Solutions, Nasal Sprays, Inhalation Capsules

6) By Transdermal And Patches: Matrix Patches, Reservoir Patches, Drug-In-Adhesive Patches, Microneedle Patches, Iontophoretic Patches

7) By Other Dosage Forms: Suppositories, Ophthalmic Preparations, Buccal Tablets, Sublingual Tablets, Implants

Which Trends Are Redefining The Future Landscape Of The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Industry?

Leading corporations in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations sector are honing their focus on innovating with solutions such as biologic formulation platforms to advance drug stability and speed up market entry for complex biologic treatments. These platforms are specialized systems crafted to develop robust and effective formulations of biologic medications, refining elements like pH, excipients, and administration techniques to amplify stability, bioavailability, and safety throughout the product lifespan. As an example, WuXi Biologics, a China-based contract research, development, and manufacturing entity, rolled out WuXiHigh 2.0, a state-of-the-art high-concentration formulation platform, in June 2025. This sophisticated platform facilitates biologic formulations with protein concentrations reaching up to 230 mg/mL, outpacing the present maximum of 200 mg/mL sanctioned by the Food and Drug Administration, while decreasing viscosity up to 90% through unique excipient combinations and sophisticated instrumentation. It responds to significant complications in creating high-concentration biologics, like viscosity and accumulation, and is constructed to enhance injection efficiency, patient adherence, and production results in both clinical and commercial phases.

Which Firms Are Considered Leaders In The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Space?

Major companies operating in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market are Thermo Fisher Scientific Inc., Lonza Group, Catalent Inc., WuXi Biologics, Samsung Biologics, Recipharm AB, Siegfried Holding AG, Evonik Industries AG, Almac Group, Aenova Group, Piramal Pharma Limited, Cambrex, Jubilant Pharmova Limited, CordenPharma, Altasciences, Hovione, Aurigene Pharmaceutical Services Ltd., DPT Laboratories Ltd., CARBOGEN AMCIS, Biopharma Group, LGM Pharma, Aarti Pharmalabs Limited.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pharmaceutical-contract-development-and-manufacturing-organization-cdmo-for-formulations-global-market-report

What Role Do Regional Policies And Investments Play In Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Expansion?

Asia-Pacific was the largest region in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25876&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model